Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 11, 2026

To Whom It May Concern

Company Name:	J-Pharma Co., Ltd.
Name of Representative:	President and CEO Masuhiro Yoshitake
Securities Code:	520A Tokyo Stock Exchange Growth Market
Contact:	Director and CFO Yutaka Fujimoto
Telephone:	+81-3-6432-4270

Notice Regarding the Recognition of Non-operating Expenses (Foreign Exchange Losses)

J-Pharma Co., Ltd. (the "Company") announces that it recorded non-operating expenses (foreign exchange losses) in the second quarter (July 1 to September 30, 2026) of the fiscal year ending March 31, 2027, as set forth below.

1. Details of Non-operating Expenses (Foreign Exchange Losses)

The Company recorded foreign exchange losses of JPY 62,626 thousand as non-operating expenses in the second quarter (July 1, 2026 to September 30, 2026) due to fluctuations in foreign exchange rates.

These losses primarily resulted from the revaluation of foreign currency-denominated assets held to cover overseas clinical development expenses and other related costs at the exchange rates prevailing as of September 30, 2026. The revaluation itself did not result in any additional cash outflow.

Including foreign exchange losses of JPY 188 thousand recorded in the first quarter (April 1 to June 30, 2026), the Company recorded total foreign exchange losses of JPY 62,815 thousand as non-operating expenses in the statement of income for the six months ended September 30, 2026 (April 1, 2026 to September 30, 2026).

2. Impact on Financial Results

The impact of these non-operating expenses (foreign exchange losses) on the Company's financial results is reflected in the "Non-consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)" announced today.

There has been no change to the Company's full-year financial forecast for the fiscal year ending March 31, 2027.